Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Splicing targeting drugs highlight intron retention as an actionable vulnerability in advanced prostate cancer

Fig. 3

Specific sequence features characterize splicing-sensitive cassette exons to RNA splicing inhibitors in 22Rv1 cells. A-F Boxplots showing comparison between up-regulated exons (red boxes in A, B, C) or down-regulated exon (green boxes in D, E, F) by indicated splicing inhibitors (Ind = indisulam, PladB = Pladienolide B, THZ = THZ531) and other not-regulated cassette exons (ref. cassette, blue box) and constitutive exons (ref. constitutive, grey box) for strength of their 3' splice-site (A, D), distance of the branchpoint from the 3' splice-site (B, E) and % of GC content (C, F). Whiskers indicate 1.5 interquartile range and highlighted circles the mean values (*p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001; ns = not significant, Welch’s t test). Number of analysed exons within each group is indicated in Additional File 2: FigureS5.

Back to article page